Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 1

1(20.0%)

N/A

1(20.0%)

5Total

Phase 3(3)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05108766Phase 3Completed

A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Role: lead

NCT05439577Unknown

A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema

Role: lead

NCT05273944Phase 1Unknown

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients

Role: lead

NCT04057326Not ApplicableUnknown

A Study of Oryz-Aspergillus Enzyme and Pancreatin Tablet in Patients With Cirrhosis and Malnutrition

Role: lead

NCT03516448Phase 3Unknown

Expanding Phase III Study of Tyroserleutide for Injection

Role: lead

NCT01489566Phase 3Unknown

Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

Role: lead

NCT00644020Unknown

Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients

Role: lead

All 7 trials loaded